Tislelizumab
Immune Checkpoint Inhibitor
Guangxi Medical Universitymonoclonal_antibodyPhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 89/ 100
Competitive context
15 Active assets in the Immune Checkpoint Inhibitor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Theprubicin Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 3 | B |
Toripalimab Sun Yat-sen University | Phase 2 | B |
LENVATINIB Guangxi Medical University | Phase 3 | B |
Ethiodized Oil Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 3 | B |
Docetaxel MacroGenics | Phase 2 | B |
View all 22 →
Same molecule, other indications
Tislelizumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →